We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and... Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. Show more
Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent...
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical...
false 0001819576 0001819576 2024-01-25 2024-01-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its...
false 0001819576 0001819576 2024-01-22 2024-01-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
false 0001819576 0001819576 2024-01-15 2024-01-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.185 | -7.43412797992 | 15.94 | 16.99 | 14.26 | 947341 | 15.75385143 | CS |
4 | 0.185 | 1.2697323267 | 14.57 | 16.99 | 13 | 948507 | 14.93221885 | CS |
12 | 3.305 | 28.864628821 | 11.45 | 16.99 | 11.11 | 963358 | 13.81280396 | CS |
26 | 8.385 | 131.632653061 | 6.37 | 16.99 | 5.71 | 908225 | 11.33373783 | CS |
52 | 7.935 | 116.348973607 | 6.82 | 16.99 | 5.71 | 721486 | 9.96012755 | CS |
156 | 12.235 | 485.515873016 | 2.52 | 16.99 | 2.25 | 753631 | 6.70917314 | CS |
260 | 3.835 | 35.119047619 | 10.92 | 16.99 | 2.25 | 631289 | 5.98878484 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions